Marinus Pharmaceuticals Inc (MRNS)
1.51
+0.06
(+4.14%)
USD |
NASDAQ |
May 03, 16:00
1.515
0.00 (0.00%)
After-Hours: 20:00
Marinus Pharmaceuticals Revenue (Quarterly): 7.19M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.19M |
| September 30, 2023 | 7.338M |
| June 30, 2023 | 6.081M |
| March 31, 2023 | 10.38M |
| December 31, 2022 | 7.162M |
| September 30, 2022 | 2.34M |
| June 30, 2022 | 1.79M |
| Date | Value |
|---|---|
| March 31, 2022 | 14.19M |
| December 31, 2021 | 1.52M |
| September 30, 2021 | 10.11M |
| June 30, 2021 | 1.905M |
| March 31, 2021 | 1.806M |
| December 31, 2020 | 1.547M |
| September 30, 2020 | 0.171M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.171M
Minimum
Sep 2020
14.19M
Maximum
Mar 2022
5.252M
Average
4.210M
Median
Revenue (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 28.10M |
| Soligenix Inc | -- |
| Actinium Pharmaceuticals Inc | -- |
| Macrogenics Inc | 9.164M |
| ADMA Biologics Inc | 73.90M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -41.77M |
| Total Expenses (Quarterly) | 42.63M |
| EPS Diluted (Quarterly) | -0.74 |
| Enterprise Value | 5.632M |
| Gross Profit Margin (Quarterly) | 87.66% |
| Profit Margin (Quarterly) | -580.9% |
| Earnings Yield | -174.2% |
| Normalized Earnings Yield | -174.17 |